This Ratio Explains Why I’d Buy AstraZeneca plc Today

AstraZeneca plc (LON:AZN) offers a 5.4% yield, but there’s a more compelling reason to buy this firm’s shares, as Roland Head explains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been much abused for its failure to invest in new products during the reign of ex-CEO David Brennan, and is undoubtedly suffering the consequences now, with both sales and earnings expected to fall for the next couple of years.

However, I reckon that investors might be overlooking one key factor, which suggests that AstraZeneca is already outrageously cheap compared to GlaxoSmithKline — and that now could be a cracking time to buy into Astra.

An important ratio

The faithful price-to-earnings ratio is a great tool for comparing the price of two similar companies, but sometimes it doesn’t tell the whole story. One problem in particular is with debt — the P/E ratio only looks at market capitalisation, and does not reflect a company’s debt levels.

For this reason, anyone considering buying a company usually shuns the P/E ratio and instead calculates the enterprise value to EBITDA ratio. Enterprise value is the true cost of a company — the sum of its market capitalisation and net debt — while EBITDA is earnings before interest, tax, depreciation and amortisation, which provides a measure of a firm’s raw profits.

By now you’ve probably guessed what’s coming — on an EV/EBITDA basis, AstraZeneca is exactly half the price of GlaxoSmithKline.

Why is AstraZeneca so cheap?

AstraZeneca currently boasts a modest EV/EBITDA ratio of 5.6, while Glaxo trades on a heady EV/EBITDA of 11.2.

Some of this pricing discrepancy can be accounted for by the fact that, unlike Astra, Glaxo has largely recovered from the patent cliff. But there must be another explanation, as well.

I think that the real reason for this massive difference in valuation is debt. Borrowing costs for big companies are low at the moment, and markets seem to be ignoring the risk that borrowing might become more expensive in the future, or that profits might fall, making it harder for companies to service their debts and pay dividends.

Glaxo has net debt of £15.7bn, giving it net gearing of 245%. AstraZeneca, in contrast, had net cash until the end of 2011, and currently has net gearing of just 5.6%.

This difference isn’t reflected in the valuations of the two companies, but I think it will be eventually, making AstraZeneca a very affordable and safe buy today, despite its short-term earnings weakness.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland owns shares in GlaxoSmithKline but does not own shares in AstraZeneca. The Motley Fool has recommended GlaxoSmithKline.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »